| Business Summary | | Insite
Vision
Incorporated
is
an
ophthalmic
product
development
company
focused
on
developing
genetically
based
tools
for
the
diagnosis,
prognosis
and
management
of
glaucoma,
as
well
as
ophthalmic
pharmaceutical
products
based
on
its
proprietary
DuraSite
eyedrop-based
drug
delivery
technology.
The
Company's
retinal
programs
include
both
therapeutic
agents
and
drug
delivery
technologies.
The
Company
is
focusing
its
research
and
development
on
expanding
its
ISV-900
technology
for
the
diagnosis,
prognosis
and
management
of
glaucoma.
It
is
also
focused
on
ISV-205,
a
DuraSite
formulation
for
the
treatment
of
glaucoma;
ISV-401,
a
DuraSite
formulation
of
a
novel
antibiotic
not
used
in
ophthalmology;
ISV-403,
a
DuraSite
formulation
of
a
second-generation
fluoroquinolone;
ISV-014,
a
retinal
drug
delivery
device,
and
treatments
for
diabetic
retinopathy
and
macular
degeneration. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Insite
Vision,
Inc.
is
engaged
in
the
development
of
ophthalmic
drugs
and
ophthalmic
drug
delivery
systems,
utilizing
a
glaucoma
genetics
program,
the
DuraSite
delivery
system,
and
a
retinal
delivery
system.
For
the
six
months
ended
6/30/01,
revenues
totalled
$3
thousand,
down
from
$800
thousand.
Net
loss
applicable
to
Common
before
accounting
change
totalled
$4.3
million,
up
from
$590
thousand.
Results
reflect
the
absence
of
license
fees,
and
increased
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| S. Kumar Chandrasekaran, Ph.D., 58 Chairman,
Pres, CEO and Chief Financial Officer | $355K | $399K | Lyle Bowman, Ph.D., 52 VP
of Devel. and Operations | 196K | 116K | Cheryl Chen, 41 Sr.
Director, Clinical Operations | -- | -- | T. Raymond Chen, Ph.D., 50 Sr.
Director, Regulatory, Quality Assurance and Quality Control | -- | -- | Sandra Heine, 39 Sr.
Director, Fin. and Admin. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|